PROLOR Biotech To Present New Preclinical Data On Its Long-Acting
Clotting Factor VIIa At Leading European Scientific Conference
WARSAW, Poland and NES-ZIONA,
Israel, Feb. 6, 2013 /PRNewswire/ -- PROLOR Biotech,
Inc. (NYSE MKT: PBTH), today announced that the company will
present new data on its long-acting clotting factor VIIa (Factor
Vlla-CTP) at the Annual Congress of the European Association for
Haemophilia and Allied Disorders (EAHAD). PROLOR's Factor
VIIa-CTP is a next-generation investigational therapy currently in
advanced preclinical development for the potential treatment of
patients with hemophilia.
Currently, factor VIIa therapy is available only as an
intravenous (IV) formulation, which can be onerous for patients.
The company will present new data at the EAHAD Congress
showing that PROLOR's long-acting Factor VIIa-CTP has demonstrated
the potential for subcutaneous (SC) administration in addition to
standard IV dosing. PROLOR researchers believe that a
long-acting factor VIIa therapy that could be administered
subcutaneously, using a simple injection, would allow children and
adults with hemophilia to easily self-administer factor Vlla at
home on a prophylactic basis, significantly improving their quality
of life.
Dr. Abraham Havron, CEO of
PROLOR, commented, "We have previously presented data in animal
models of hemophilia showing that Factor Vlla-CTP demonstrated
superiority across key efficacy and safety parameters as compared
to current factor VIIa therapy. The potential for SC
administration may represent a major competitive advantage for our
long-acting Factor Vlla-CTP, and we expect to initiate a Phase II
clinical trial in hemophilia patients in late 2013 or early
2014."
The data will be presented from 5:00-8:00pm local time on February 6, 2013 by Dr. Gili Hart, Director of Pre-Clinical Affairs at
PROLOR and head of the company's long-acting clotting factors
program. The European Association for Haemophilia and Allied
Disorders 6th Annual Congress is being held February 6-8, 2013 in Warsaw, Poland. For more information,
visit: http://eahad2013.pl/index.html.
About Hemophilia
Patients with hemophilia do not
produce adequate amounts of the clotting factors that are necessary
for effective blood clotting. In severe hemophiliacs even a
minor injury can result in blood loss that may continue for days or
weeks, with the potential for debilitating permanent damage to
joints and other organs and premature death. According to the
World Health Organization, more than 400,000 people worldwide have
hemophilia. Commercially available recombinant clotting
factors have enabled many hemophiliacs to live near-normal lives,
but frequent injections, infusions and/or blood transfusions may be
required.
About PROLOR
PROLOR Biotech, Inc. is a clinical stage
biopharmaceutical company applying unique technologies, including
patented CTP technology and its long-acting reversible-pegylation
technology, primarily to develop longer-acting proprietary versions
of already approved therapeutic proteins that currently generate
billions of dollars in annual global sales. The CTP
technology is applicable to virtually all proteins. PROLOR is
developing a long-acting version of human growth hormone, which
successfully completed a Phase II clinical trial. It also is
developing long-acting versions of factor VIIa and factor IX for
hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for
diabetes and obesity, all of which are in preclinical
development. For more information, visit
www.prolor-biotech.com.
Safe Harbor Statement: This press release
contains forward-looking statements, which may be identified by
words such as "expects," "plans," "projects," "will," "may,"
"anticipates," "believes," "should," "would", "intends,"
"estimates," "suggests," "has the potential to" and other words of
similar meaning, including statements regarding the results of
current clinical studies and preclinical experiments and the
effectiveness of PROLOR's long-acting protein programs, which are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Investors are
cautioned that forward-looking statements involve risks and
uncertainties that may affect PROLOR's business and prospects,
including the risks that PROLOR may not succeed in generating any
revenues or developing any commercial products, including any
long-acting versions of human growth hormone, erythropoietin,
interferon beta, GLP-1 and other products; that the long-acting
products in development may fail, may not achieve the expected
results or effectiveness and/or may not generate data that would
support the approval or marketing of these products for the
indications being studied or for other indications; that ongoing
studies may not continue to show substantial or any activity; that
the actual dollar amount of any grants from Israel's Office of the Chief Scientist is
uncertain and is subject to policy changes of the Israeli
government, and that such grants may be insufficient to assist with
product development; and other risks and uncertainties that may
cause results to differ materially from those set forth in the
forward-looking statements. The results of clinical trials in
humans may produce results that differ significantly from the
results of clinical and other trials in animals. The results of
early-stage trials may differ significantly from the results of
more developed, later-stage trials. The development of any products
using the CTP platform technology could also be affected by a
number of other factors, including unexpected safety, efficacy or
manufacturing issues, additional time requirements for data
analyses and decision making, the impact of pharmaceutical industry
regulation, the impact of competitive products and pricing and the
impact of patents and other proprietary rights held by competitors
and other third parties. In addition to the risk factors
described above, investors should consider the economic,
competitive, governmental, technological and other factors
discussed in PROLOR's filings with the Securities and Exchange
Commission. The forward-looking statements contained in this
press release speak only as of the date the statements were made,
and we do not undertake any obligation to update forward-looking
statements, except as required under applicable law.
PROLOR
CONTACT:
|
MEDIA
CONTACT:
|
Shai
Novik, President
|
Barbara
Lindheim
|
PROLOR
Biotech,
Inc.
|
BLL
Partners, LLC
|
Tel: +1
866 644-7811
|
+1 212
584-2276
|
Email:
shai@prolor-biotech.com
|
blindheim@bllbiopartners.com
|
SOURCE PROLOR Biotech, Inc.